SEC Form 4 · accession 0001140361-17-038267
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory J. Davis
Other
Period of report
Oct 10, 2017
Accepted (ET)
Oct 11, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $21.67 | holding | — | — | — | — | Jun 26, 2025 | ADSs | 50,000 | 50,000 | D |
| Stock Option (right to buy)F4 | $14.35 | holding | — | — | — | — | Dec 10, 2025 | ADSs | 50,000 | 50,000 | D |
| Stock Option (right to buy)F5 | $10.40 | holding | — | — | — | — | Dec 14, 2026 | ADSs | 65,000 | 65,000 | D |
Explanation of responses
- F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- F2Includes (a) 20,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (b) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- F3Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 06/26/2015 grant date.
- F4Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- F5Options become exercisable as to 16,250 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Remarks
This filing constitutes a Form 4 exit filing for the Reporting Person as the Reporting Person is no longer subject to Section 16 under the Securities Exchange Act of 1934.